In the next year or so, the race to develop new drug therapies for aggressive end-stage prostate cancer could heat up considerably, with several late-stage therapies due to report data in 2009 and early 2010. At the American Society of Clinical Oncology's Genitourinary Cancers Symposium Feb. 26-28 in Orlando, investigators released positive data on several compounds to treat prostate cancer that is resistant to hormone therapy or other methods of castration, which is also the most deadly form of...